AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MEDICAL
Merck said to hide Vioxx concerns
The pharmaceutical giant fell 10% to 28.28 after a news report said as early as '00 Merck knew its arthritis drug Vioxx was linked to heart problems. The Wall Street Journal cited internal e-mails and marketing materials that also showed Merck tried to discredit evidence against Vioxx. In late Sept., Merck pulled the drug from the shelves, prompting a wave of lawsuits and cutting into Q3 earnings.
Humana beats, raises guidance
The health plan provider earned 52 cents a share in Q3, up 37% and 8 cents over views. Revenue rose 2.25% to $3.18 bil. Profit from its commercial business climbed 49% while those from its government segment climbed 32%. Humana raised its '04 profit forecast to $1.66-$1.69 a share. Views were for $1.65. It also lifted its '05 guidance. Shares jumped 6.5% to 20.35.
Icahn: King warning shows risk
Financier Carl Icahn said King Pharmaceutical's warning that it may need to restate earnings reinforces his position that Mylan Labs' pending buyout of King is "extremely risky." Icahn, who owns 9.8% of Mylan Labs, has ...